Evolution of the Average Target: BioXcel Therapeutics

Evolution of the Target Price: BioXcel Therapeutics

Changes in Analyst Recommendations: BioXcel Therapeutics

80ad3ad3e328fe3986b44.dFB1sj4PJ4TLEZaB3JP6fb9eepoYKCBOd7rTOPVwbIo.OH0C43dmQtySYfDruduVBdAyO-lJZ08kBPaaUaUYFORBPybXdGpQt4Rm-Q~ac6d9d57562c0ddf95df9231d6d6d3b8
BofA Securities Downgrades BioXcel Therapeutics to Underperform From Buy, Adjusts Price Target to $0.25 From $7 01-07 MT
Mizuho Adjusts PT on BioXcel Therapeutics to $1 From $4 on Solvency Concerns, Uncertainty; Keeps Neutral Rating 24-08-12 MT
UBS Adjusts Price Target on BioXcel Therapeutics to $1 From $3.50, Maintains Neutral Rating 24-08-09 MT
Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating 24-03-14 MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating 24-03-13 MT
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9 24-02-21 MT
Truist Securities Downgrades BioXcel Therapeutics to Hold From Buy 23-10-05 MT
HC Wainwright Lowers Price Target on BioXcel Therapeutics to $11 From $60, Maintains Buy Rating 23-08-18 MT
UBS Adjusts BioXcel Therapeutics Price Target to $9 From $48, Maintains Buy Rating 23-08-16 MT
Goldman Sachs Cuts Price Target on BioXcel Therapeutics to $4 From $12, Maintains Neutral Rating 23-08-15 MT
Truist Securities Adjusts Price Target on BioXcel Therapeutics to $31 From $71, Keeps Buy Rating 23-08-15 MT
Canaccord Genuity Adjusts Price Target on BioXcel Therapeutics to $20 From $75, Keeps Buy Rating 23-08-15 MT
Mizuho Downgrades BioXcel Therapeutics to Neutral From Buy Amid Restructuring and Strategic Reprioritization, Slashes Price Target to $4 From $40 23-08-15 MT
Guggenheim Downgrades BioXcel Therapeutics to Neutral From Buy 23-07-17 MT
HC Wainwright Cuts Price Target on BioXcel Therapeutics to $60 From $66, Maintains Buy Rating 23-07-03 MT
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $25 From $28, Maintains Neutral Rating 23-05-26 MT
Mizuho Securities Adjusts BioXcel Therapeutics Price Target to $40 From $38, Maintains Buy Rating 23-05-10 MT
Guggenheim Adjusts Price Target on BioXcel Therapeutics to $46 From $50, Maintains Buy Rating 23-05-09 MT
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $66 From $79, Keeps Buy Rating 23-03-21 MT
UBS Adjusts BioXcel Therapeutics Price Target to $48 From $52, Maintains Buy Rating 23-03-13 MT
Jefferies Downgrades BioXcel Therapeutics to Hold From Buy, Adjusts Price Target to $22 From $20 23-03-10 MT
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $79 From $73, Maintains Buy Rating 23-02-21 MT
UBS Adjusts BioXcel Therapeutics Price Target to $52 From $23, Maintains Buy Rating 23-02-15 MT
Mizuho Securities Adjusts Price Target on BioXcel Therapeutics to $38 From $24, Maintains Buy Rating 23-02-08 MT
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $26 From $16, Maintains Neutral Rating 23-01-26 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.640USD
Average target price
37.00USD
Spread / Average Target
+1,301.52%
High Price Target
80.00USD
Spread / Highest target
+2,930.30%
Low Price Target
4.000USD
Spread / Lowest Target
+51.52%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
Canaccord Genuity
UBS
Truist Securities
HC Wainwright
Goldman Sachs
Mizuho Securities
Guggenheim
Jefferies & Co.
Berenberg Bank
Trading Rating
Investor Rating
ESG MSCI
BB
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BTAI Stock
  4. Consensus BioXcel Therapeutics